Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Anatomic Stage III Breast Cancer AJCC v8|Anatomic Stage IV Breast Cancer AJCC v8|Metastatic HER2-Negative Breast Carcinoma|Unresectable HER2-Negative Breast Carcinoma
Interventions: DRUG: Alpelisib|PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Bone Scan|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|DRUG: Olaparib|PROCEDURE: Positron Emission Tomography
Sponsor: National Cancer Institute (NCI)